The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism
Abstract
The clinical diagnosis of progressive supranuclear palsy (PSP) relies on the identification of characteristic signs and symptoms. A proportion of pathologically diagnosed cases do not develop these classic features, prove difficult to diagnose during life and are considered as atypical PSP. The aim of this study was to examine the apparent clinical dichotomy between typical and atypical PSP, and to compare the biochemical and genetic characteristics of these groups. In 103 consecutive cases of pathologically confirmed PSP, we have identified two clinical phenotypes by factor analysis which we have named Richardson's syndrome (RS) and PSP-parkinsonism (PSP-P). Cases of RS syndrome made up 54% of all cases, and were characterized by the early onset of postural instability and falls, supranuclear vertical gaze palsy and cognitive dysfunction. A second group of 33 (32%) were characterized by asymmetric onset, tremor, a moderate initial therapeutic response to levodopa and were frequently confused with Parkinson's disease (PSP-P). Fourteen cases (14%) could not be separated according to these criteria. In RS, two-thirds of cases were men, whereas the sex distribution in PSP-P was even. Disease duration in RS was significantly shorter (5.9 versus 9.1 years, P < 0.001) and age at death earlier (72.1 versus 75.5 years, P = 0.01) than in PSP-P. The isoform composition of insoluble tangle-tau isolated from the basal pons also differed significantly. In RS, the mean four-repeat:three-re…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NFTs in AD contain a mixture of 4R-Tau and 3R-Tau1, while deposits in progressive supranuclear palsy predominantly contain 4R-Tau15, and Pick’s disease inclusions mostly have 3R-Tau16.”
From Liquid–liquid phase separation of the microtubule-binding repeats of the Alzheimer-related protein Tau (2017) · cites this paper as [15]
Citations
Cites
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Litvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., Goetz, C. G., Golbe, L. I., Grafman, J., Growdon, J. H., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.1 · Cited by 2,538
Association of an Extended Haplotype in the Tau Gene with Progressive Supranuclear Palsy
Baker, M., Litvan, I., Houlden, H., Adamson, J., Dickson, D., Perez-Tur, J., Hardy, J., Lynch, T., Bigio, E., & Hutton, M. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.4.711 · Cited by 781
Research works printed but not linked: 63
- Albert ML, Feldman RG, Willis AL. The ‘subcortical dementia’ of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry1974; 37: 121–30. · DOI · Paper page
- Arai T, Ikeda K, Akiyama H, et al. Distinct isoforms of tau aggregated in neurons and glial cells in brains of patients with Pick's disease, corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol (Berl)2001; 101: 167–73. · DOI · Paper page
- Arnold G, Tatsch K, Oertel WH, et al. Clinical progressive supranuclear palsy: differential diagnosis by IBZM-SPECT and MRI. J Neural Transm Suppl1994; 42: 111–8. · doi:10.1007/978-3-7091-6641-3_9
- Avila J, Lucas JJ, Perez M, Hernandez F. Role of tau protein in both physiological and pathological conditions. Physiol Rev2004; 84: 361–84. · DOI · Paper page
- Bergeron C, Pollanen MS, Weyer L, Lang AE. Cortical degeneration in progressive supranuclear palsy. A comparison with cortical-basal ganglionic degeneration. J Neuropathol Exp Neurol1997; 56: 726–34. · DOI
- Bigio EH, Brown DF, White CL. Progressive supranuclear palsy with dementia: cortical pathology. J Neuropathol Exp Neurol1999; 58: 359–64. · DOI
- Birdi S, Rajput AH, Fenton M, et al. Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases. Mov Disord2002; 17: 1255–64. · DOI
- Braak H, Jellinger K, Braak E, Bohl J. Allocortical neurofibrillary changes in progressive supranuclear palsy. Acta Neuropathol (Berl)1992; 84: 478–83. · DOI
- Brion JP, Couck AM, Passareiro E, Flament-Durand J. Neurofibrillary tangles of Alzheimer's disease: an immunohistochemical study. J Submicrosc Cytol1985; 17: 89–96.
- Brion JP, Couck AM, Robertson J, Loviny TL, Anderton BH. Neurofilament monoclonal antibodies RT97 and 8D8 recognize different modified epitopes in paired helical filament-tau in Alzheimer's disease. J Neurochem1993; 60: 1372–82. · DOI
- Buee L, Delacourte A. Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease. Brain Pathol1999; 9: 681–93. · DOI · Paper page
- Buee L, Delacourte A, Wilhelmsen KC, Miller B, Geschwind D. Neuronal subpopulations and genetic background in tauopathies: a catch 22 story? Neurobiol Aging2001; 22: 115–21. · DOI
- Chambers CB, Lee JM, Troncoso JC, Reich S, Muma NA. Overexpression of four-repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer's disease. Ann Neurol1999; 46: 325–32. · doi:10.1002/1531-8249(199909)46:3<325::aid-ana8>3.0.co;2-v
- Conrad C, Andreadis A, Trojanowski JQ, et al. Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol1997; 41: 277–81. · DOI · Paper page
- Daniel SE, De Bruin V, Lees AJ. The clinical and pathological spectrum of Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy): a reappraisal. Brain1995; 118: 759–70. · DOI · Paper page
- Davis PH, Bergeron C, McLachlan DR. Atypical presentation of progressive supranuclear palsy. Ann Neurol1985; 17: 337–43. · DOI · Paper page
- de Silva R, Hope A, Pittman A, et al. Strong association of the Saitohin gene Q7 variant with progressive supranuclear palsy. Neurology2003; 61: 407–9. · DOI
- de Silva R, Lashley T, Gibb G, et al. Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies. Neuropathol Appl Neurobiol2003; 29: 288–302. · DOI · Paper page
- Delacourte A, Robitaille Y, Sergeant N, et al. Specific pathological Tau protein variants characterize Pick's disease. J Neuropathol Exp Neurol1996; 55: 159–68. · DOI · Paper page
- Dubas F, Gray F, Escourolle R. [Steele-Richardson-Olszewski disease without ophthalmoplegia. 6 clinico-anatomic cases]. Rev Neurol (Paris)1983; 139: 407–16.
- Flament S, Delacourte A, Hemon B, Defossez A. Characterization of two pathological tau protein, variants in Alzheimer brain cortices. J Neurol Sci1989; 92: 133–41. · DOI
- Forman MS. Genotype-phenotype correlations in FTDP-17: does form follow function? Exp Neurol2004; 187: 229–34. · DOI
- Gibb GM, de Silva R, Revesz T, Lees AJ, Anderton BH, Hanger DP. Differential involvement and heterogeneous phosphorylation of tau isoforms in progressive supranuclear palsy. Brain Res Mol Brain Res2004; 121: 95–101. · DOI
- Goedert M, Jakes R, Crowther RA, Hasegawa M, Smith MJ, Spillantini MG. Intraneuronal filamentous tau protein and alpha-synuclein deposits in neurodegenerative diseases. Biochem Soc Trans1998; 26: 463–71. · DOI
- Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem1986; 261: 6084–9. · DOI
- Hanger DP, Brion JP, Gallo JM, Cairns NJ, Luthert PJ, Anderton BH. Tau in Alzheimer's disease and Down's syndrome is insoluble and abnormally phosphorylated. Biochem J1991; 275: 99–104. · DOI
- Hanger DP, Betts JC, Loviny TL, Blackstock WP, Anderton BH. New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J Neurochem1998; 71: 2465–76. · DOI · Paper page
- Hanger DP, Gibb GM, de Silva R, et al. The complex relationship between soluble and insoluble tau in tauopathies revealed by efficient dephosphorylation and specific antibodies. FEBS Lett2002; 531: 538–42. · DOI
- Hauw JJ, Verny M, Delaere P, Cervera P, He Y, Duyckaerts C. Constant neurofibrillary changes in the neocortex in progressive supranuclear palsy. Basic differences with Alzheimer's disease and aging. Neurosci Lett1990; 119: 182–6. · DOI · Paper page
- Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology2001; 57: 1497–9. · DOI · Paper page
- Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain2002; 125: 861–70. · DOI · Paper page
- Jellinger K. Progressive supranuclear palsy (subcortical argyrophilic dystrophy). Acta Neuropathol (Berl)1971; 19: 347–52. · DOI
- Juncos JL, Hirsch EC, Malessa S, Duyckaerts C, Hersh LB, Agid Y. Mesencephalic cholinergic nuclei in progressive supranuclear palsy. Neurology1991; 41: 25–30. · DOI
- Ksiezak-Reding H, Morgan K, Mattiace LA, et al. Ultrastructure and biochemical composition of paired helical filaments in corticobasal degeneration. Am J Pathol1994; 145: 1496–508.
- Landwehrmeyer B, Palacios JM. Alterations of neurotransmitter receptors and neurotransmitter transporters in progressive supranuclear palsy. J Neural Transm Suppl1994; 42: 229–46. · DOI
- Lieberman AP, Trojanowski JQ, Lee VM, et al. Cognitive, neuroimaging, and pathological studies in a patient with Pick's disease. Ann Neurol1998; 43: 259–65. · DOI · Paper page
- Litvan I, Hauw JJ, Bartko JJ, et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol1996; 55: 97–105. · DOI · Paper page
- Litvan I, Grimes DA, Lang AE, et al. Clinical features differentiating patients with postmortem confirmed progressive supranuclear palsy and corticobasal degeneration. J Neurol1999; 246 Suppl 2: II1NII5. · DOI
- Litvan I, Bhatia KP, Burn DJ, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord2003; 18: 467–86. · DOI · Paper page
- Liu WK, Le TV, Adamson J, et al. Relationship of the extended tau haplotype to tau biochemistry and neuropathology in progressive supranuclear palsy. Ann Neurol2001; 50: 494–502. · DOI
- Maher ER, Lees AJ. The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology1986; 36: 1005–8. · DOI · Paper page
- Mailliot C, Sergeant N, Bussiere T, Caillet-Boudin ML, Delacourte A, Buee L. Phosphorylation of specific sets of tau isoforms reflects different neurofibrillary degeneration processes. FEBS Lett1998; 433: 201–4. · DOI
- Maraganore DM, Anderson DW, Bower JH, McDonnell SK, Rocca WA. Autopsy patterns for Parkinson's disease and related disorders in Olmsted County, Minnesota. Neurology1999; 53: 1342–4. · DOI
- Masliah E, Hansen LA, Quijada S, et al. Late onset dementia with argyrophilic grains and subcortical tangles or atypical progressive supranuclear palsy? Ann Neurol1991; 29: 389–96. · DOI
- Matsuo H, Takashima H, Kishikawa M, et al. Pure akinesia: an atypical manifestation of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry1991; 54: 397–400. · DOI
- Morris HR, Gibb G, Katzenschlager R, et al. Pathological, clinical and genetic heterogeneity in progressive supranuclear palsy. Brain2002; 125:969–75. · DOI
- Motoi Y, Takanashi M, Itaya M, Ikeda K, Mizuno Y, Mori H. Glial localization of four-repeat tau in atypical progressive supranuclear palsy. Neuropathology2004; 24: 60–5. · DOI
- Mulot SF, Hughes K, Woodgett JR, Anderton BH, Hanger DP. PHF-tau from Alzheimer's brain comprises four species on SDS-PAGE which can be mimicked by in vitro phosphorylation of human brain tau by glycogen synthase kinase-3 beta. FEBS Lett1994; 349: 359–64. · DOI
- Nath U, Ben-Shlomo Y, Thomson RG, Lees AJ, Burn DJ. Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study. Neurology2003; 60: 910–6. · DOI · Paper page
- Parvizi J, Van Hoesen GW, Damasio A. The selective vulnerability of brainstem nuclei to Alzheimer's disease. Ann Neurol2001; 49: 53–66. · DOI · Paper page
- Pierot L, Desnos C, Blin J, et al. D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy. J Neurol Sci1988; 86: 291–306. · DOI
- Pittman AM, Myers AJ, Duckworth J, et al. The structure of the tau haplotype in controls and in progressive supranuclear palsy. Hum Mol Genet2004; 13: 1267–74. · DOI
- Revesz T, Sangha H, Daniel SE. The nucleus raphe interpositus in the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Brain1996; 119: 1137–43. · DOI
- Ruberg M, Javoy-Agid F, Hirsch E, et al. Dopaminergic and cholinergic lesions in progressive supranuclear palsy. Ann Neurol1985; 18:523–9. · DOI · Paper page
- Schraen-Maschke S, Dhaenens CM, Delacourte A, Sablonniere B. Microtubule-associated protein tau gene: a risk factor in human neurodegenerative diseases. Neurobiol Dis2004; 15: 449–60. · DOI
- Sham PC, Curtis D. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet1995; 59: 97–105. · DOI · Paper page
- Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brainstem, basal ganglia and cerebellum with vertical supranuclear gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol1964; 10: 333–59. · DOI · Paper page
- Suzuki M, Desmond TJ, Albin RL, Frey KA. Cholinergic vesicular transporters in progressive supranuclear palsy. Neurology2002; 58: 1013–8. · DOI
- Takanashi M, Mori H, Arima K, Mizuno Y, Hattori N. Expression patterns of tau mRNA isoforms correlate with susceptible lesions in progressive supranuclear palsy and corticobasal degeneration. Brain Res Mol Brain Res2002; 104: 210–9. · DOI
- Vermersch P, Robitaille Y, Bernier L, Wattez A, Gauvreau D, Delacourte A. Biochemical mapping of neurofibrillary degeneration in a case of progressive supranuclear palsy: evidence for general cortical involvement. Acta Neuropathol (Berl)1994; 87: 572–7. · DOI
- Verny M, Duyckaerts C, Agid Y, Hauw JJ. The significance of cortical pathology in progressive supranuclear palsy. Clinico-pathological data in 10 cases. Brain1996; 119: 1123–36. · DOI
- Verny M, Jellinger KA, Hauw JJ, Bancher C, Litvan I, Agid Y. Progressive supranuclear palsy: a clinicopathological study of 21 cases. Acta Neuropathol (Berl)1996; 91: 427–31. · DOI
- Wenham PR, Price WH, Blandell G. Apolipoprotein E genotyping by one-stage PCR. Lancet1991; 337: 1158–9. · DOI · Paper page
Cited by
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
Höglinger, G. U., Respondek, G., Stamelou, M., Kurz, C., Josephs, K. A., Lang, A. E., Mollenhauer, B., Müller, U., Nilsson, C., Whitwell, J. L., et al. (2017) · Movement Disorders · doi:10.1002/mds.26987 · Cited by 2,359
Lees, A. J., Hardy, J., & Revesz, T. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60492-x · Cited by 1,956
Self-citationClinical Neurology and Epidemiology of the Major Neurodegenerative Diseases
Erkkinen, M. G., Kim, M.-O., & Geschwind, M. D. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a033118 · Cited by 1,124
The diagnosis of Parkinson’s disease
Tolosa, E., Wenning, G., & Poewe, W. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70285-4 · Cited by 902
Structure-based classification of tauopathies
Shi, Y., Zhang, W., Yang, Y., Murzin, A. G., Falcon, B., Kotecha, A., van Beers, M., Tarutani, A., Kametani, F., Garringer, H. J., et al. (2021) · Nature · doi:10.1038/s41586-021-03911-7 · Cited by 878
Parkinson's Disease and Parkinsonism: Neuropathology
Dickson, D. W. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009258 · Cited by 847
Ambadipudi, S., Biernat, J., Riedel, D., Mandelkow, E., & Zweckstetter, M. (2017) · Nature Communications · doi:10.1038/s41467-017-00480-0 · Cited by 782
Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech
Josephs, K. A. (2006) · Brain · doi:10.1093/brain/awl078 · Cited by 689
Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges
Williams, D. R., & Lees, A. J. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70042-0 · Cited by 650
Self-citationA clinical rating scale for progressive supranuclear palsy
Golbe, L. I., & Ohman-Strickland, P. A. (2007) · Brain · doi:10.1093/brain/awm032 · Cited by 614
Arendt, T., Stieler, J. T., & Holzer, M. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.08.018 · Cited by 609
Distribution patterns of tau pathology in progressive supranuclear palsy
Kovacs, G. G., Lukic, M. J., Irwin, D. J., Arzberger, T., Respondek, G., Lee, E. B., Coughlin, D., Giese, A., Grossman, M., Kurz, C., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02158-2 · Cited by 483
A clinico-pathological study of subtypes in Parkinson's disease
Selikhova, M., Williams, D. R., Kempster, P. A., Holton, J. L., Revesz, T., & Lees, A. J. (2009) · Brain · doi:10.1093/brain/awp234 · Cited by 461
Self-citationNeuropathological background of phenotypical variability in frontotemporal dementia
Josephs, K. A., Hodges, J. R., Snowden, J. S., Mackenzie, I. R., Neumann, M., Mann, D. M., & Dickson, D. W. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0839-6 · Cited by 459
Clinical outcomes of progressive supranuclear palsy and multiple system atrophy
O'Sullivan, S. S., Massey, L. A., Williams, D. R., Silveira-Moriyama, L., Kempster, P. A., Holton, J. L., Revesz, T., & Lees, A. J. (2008) · Brain · doi:10.1093/brain/awn065 · Cited by 423
Self-citationClinical Approach to Parkinson's Disease: Features, Diagnosis, and Principles of Management
Massano, J., & Bhatia, K. P. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a008870 · Cited by 422
Quattrone, A., Nicoletti, G., Messina, D., Fera, F., Condino, F., Pugliese, P., Lanza, P., Barone, P., Morgante, L., Zappia, M., et al. (2008) · Radiology · doi:10.1148/radiol.2453061703 · Cited by 420
Williams, D. R., Holton, J. L., Strand, C., Pittman, A., de Silva, R., Lees, A. J., & Revesz, T. (2007) · Brain · doi:10.1093/brain/awm104 · Cited by 417
Self-citationA clinicopathological approach to the diagnosis of dementia
Elahi, F. M., & Miller, B. L. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.96 · Cited by 412
Does corticobasal degeneration exist? A clinicopathological re-evaluation
Ling, H., O'Sullivan, S. S., Holton, J. L., Revesz, T., Massey, L. A., Williams, D. R., Paviour, D. C., & Lees, A. J. (2010) · Brain · doi:10.1093/brain/awq123 · Cited by 394
Self-citationNeuropathology of variants of progressive supranuclear palsy
Dickson, D. W., Ahmed, Z., Algom, A. A., Tsuboi, Y., & Josephs, K. A. (2010) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32833be924 · Cited by 386
Respondek, G., Stamelou, M., Kurz, C., Ferguson, L. W., Rajput, A., Chiu, W. Z., van Swieten, J. C., Troakes, C., al Sarraj, S., Gelpi, E., et al. (2014) · Movement Disorders · doi:10.1002/mds.26054 · Cited by 384
Neuropathology of Frontotemporal Lobar Degeneration-Tau (FTLD-Tau)
Dickson, D. W., Kouri, N., Murray, M. E., & Josephs, K. A. (2011) · Journal of Molecular Neuroscience · doi:10.1007/s12031-011-9589-0 · Cited by 380
Narasimhan, S., Guo, J. L., Changolkar, L., Stieber, A., McBride, J. D., Silva, L. V., He, Z., Zhang, B., Gathagan, R. J., Trojanowski, J. Q., et al. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.1230-17.2017 · Cited by 374
Eye movements in patients with neurodegenerative disorders
Anderson, T. J., & MacAskill, M. R. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.273 · Cited by 363
Kovacs, G. G., Milenkovic, I., Wöhrer, A., Höftberger, R., Gelpi, E., Haberler, C., Hönigschnabl, S., Reiner-Concin, A., Heinzl, H., Jungwirth, S., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1157-y · Cited by 361
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS Study
Bensimon, G., Ludolph, A., Agid, Y., Vidailhet, M., Payan, C., & Leigh, P. N. (2009) · Brain · doi:10.1093/brain/awn291 · Cited by 347
Progressive Supranuclear Palsy: Pathology and Genetics
Dickson, D. W., Rademakers, R., & Hutton, M. L. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00054.x · Cited by 314
Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy
Brown, R. G., Lacomblez, L., Landwehrmeyer, B. G., Bak, T., Uttner, I., Dubois, B., Agid, Y., Ludolph, A., Bensimon, G., Payan, C., et al. (2010) · Brain · doi:10.1093/brain/awq158 · Cited by 314
EFNS‐ENS Guidelines on the diagnosis and management of disorders associated with dementia
Sorbi, S., Hort, J., Erkinjuntti, T., Fladby, T., Gainotti, G., Gurvit, H., Nacmias, B., Pasquier, F., Popescu, B. O., Rektorova, I., et al. (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2012.03784.x · Cited by 306
Phosphorylated α-Synuclein in Parkinson’s Disease
Wang, Y., Shi, M., Chung, K. A., Zabetian, C. P., Leverenz, J. B., Berg, D., Srulijes, K., Trojanowski, J. Q., Lee, V. M.-Y., Siderowf, A. D., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002566 · Cited by 275
Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?
Whitwell, J. L., Höglinger, G. U., Antonini, A., Bordelon, Y., Boxer, A. L., Colosimo, C., van Eimeren, T., Golbe, L. I., Kassubek, J., Kurz, C., et al. (2017) · Movement Disorders · doi:10.1002/mds.27038 · Cited by 260
Williams, D. R. (2006) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2006.01153.x · Cited by 259
Self-citationCorticobasal degeneration: a pathologically distinct 4R tauopathy
Kouri, N., Whitwell, J. L., Josephs, K. A., Rademakers, R., & Dickson, D. W. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.43 · Cited by 246
Voxel-based morphometry in autopsy proven PSP and CBD
Josephs, K. A., Whitwell, J. L., Dickson, D. W., Boeve, B. F., Knopman, D. S., Petersen, R. C., Parisi, J. E., & Jack, C. R. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.09.019 · Cited by 234
Neuropathology of multiple system atrophy: New thoughts about pathogenesis
Jellinger, K. A. (2014) · Movement Disorders · doi:10.1002/mds.26052 · Cited by 181
[18F]AV‐1451 tau positron emission tomography in progressive supranuclear palsy
Whitwell, J. L., Lowe, V. J., Tosakulwong, N., Weigand, S. D., Senjem, M. L., Schwarz, C. G., Spychalla, A. J., Petersen, R. C., Jack, C. R., & Josephs, K. A. (2017) · Movement Disorders · doi:10.1002/mds.26834 · Cited by 159
Parkinsonism, movement disorders and genetics in frontotemporal dementia
Baizabal-Carvallo, J. F., & Jankovic, J. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.14 · Cited by 121
Subcortical 18F‐AV‐1451 binding patterns in progressive supranuclear palsy
Cho, H., Choi, J. Y., Hwang, M. S., Lee, S. H., Ryu, Y. H., Lee, M. S., & Lyoo, C. H. (2017) · Movement Disorders · doi:10.1002/mds.26844 · Cited by 119
Rational therapeutic approaches to progressive supranuclear palsy
Stamelou, M., de Silva, R., Arias-Carrion, O., Boura, E., Hollerhage, M., Oertel, W. H., Muller, U., & Hoglinger, G. U. (2010) · Brain · doi:10.1093/brain/awq115 · Cited by 91
Self-citationNeuroinflammation and Tau Colocalize in vivo in Progressive Supranuclear Palsy
Malpetti, M., Passamonti, L., Rittman, T., Jones, P. S., Vázquez Rodríguez, P., Bevan‐Jones, W. R., Hong, Y. T., Fryer, T. D., Aigbirhio, F. I., O'Brien, J. T., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25911 · Cited by 83
Chemosensory dysfunction in neurodegenerative diseases
(2019) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-63855-7.00020-4 · Cited by 78
Boeve, B. F. (2007) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31815bf454 · Cited by 73
Emotion recognition in progressive supranuclear palsy
Ghosh, B. C. P., Rowe, J. B., Calder, A. J., Hodges, J. R., & Bak, T. H. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.155846 · Cited by 68
Schofield, E. C., Hodges, J. R., Macdonald, V., Cordato, N. J., Kril, J. J., & Halliday, G. M. (2011) · Movement Disorders · doi:10.1002/mds.23295 · Cited by 48
Bharti, K., Bologna, M., Upadhyay, N., Piattella, M. C., Suppa, A., Petsas, N., Giannì, C., Tona, F., Berardelli, A., & Pantano, P. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00248 · Cited by 44
How do patients with parkinsonism present? A clinicopathological study
Williams, D. R., & Lees, A. J. (2009) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2008.01635.x · Cited by 44
Self-citationWilke, C., Pomper, J. K., Biskup, S., Puskás, C., Berg, D., & Synofzik, M. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8021-7 · Cited by 43
Bouwmans, A. E. P., Vlaar, A. M. M., Srulijes, K., Mess, W. H., & Weber, W. E. J. (2010) · International review of neurobiology · doi:10.1016/s0074-7742(10)90009-3 · Cited by 40
Concomitant progressive supranuclear palsy and chronic traumatic encephalopathy in a boxer
Ling, H., Kara, E., Revesz, T., Lees, A. J., Plant, G. T., Martino, D., Houlden, H., Hardy, J., & Holton, J. L. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-24 · Cited by 27
Self-citationDiagnosing progressive supranuclear palsy: Role of biological and neuroimaging markers
Benussi A, B. B. (2014) · Journal of Alzheimer's Disease & Parkinsonism · doi:10.4172/2161-0460.1000168 · Cited by 6
Metadata
- Authors
- Williams, D. R., de Silva, R., Paviour, D. C., Pittman, A., Watt, H. C., Kilford, L., Holton, J. L., Revesz, T., & Lees, A. J.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-03-23
- Volume
- 128
- Issue
- 6
- Pages
- 1247-1258
- ISSN
- 1460-2156
- 0006-8950
- Cited by
- 667
- References
- 4
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.